Annual General Meeting 2025: Resolutions and Strategies
The latest Annual General Meeting of Evotec SE provided clarity in a challenging market environment and presented important strategic issues for investors. Here are the key points discussed at the meeting:
- Virtual Annual General Meetings: Shareholders voted in favor of amending the articles of association to permanently allow virtual annual general meetings. This facilitates participation and flexibility for future meetings.
- Discharge of the Executive Board and Supervisory Board: Shareholders overwhelmingly discharged the Executive Board and Supervisory Board for the fiscal year 2024.
- Adjustment of the Share Performance Plan 2022: The plan was updated to optimize the company’s compensation structure.
- Confirmation of BDO AG as Auditor: BDO AG was confirmed as auditor for 2025, ensuring continuity in financial auditing.
- New Executive Board Members: The Annual General Meeting provided the opportunity to introduce new Executive Board members Aurélie Dalbiez (Chief People Officer) and Paul Hitchin (CFO). These appointments are aimed at bringing fresh perspectives to the executive leadership.
- Strategic Orientation: Under the motto “Pioneering Drug Discovery,” CEO Dr. Christian Wojczewski presented the company’s strategic direction.
Market Environment and Corporate Strategy
Evotec SE operates in a challenging market environment characterized by change. Despite these challenges, the company has presented its strategic plans to continue succeeding as a global player in drug research and development. With over 4,800 experts worldwide, Evotec focuses on innovation and expertise.
Shareholders demonstrated significant support for the adopted course with a presence of 46.45% of the share capital. This support could help the company assert itself in a tense biotech market.